IYF

A new breed of exchange-traded funds that hide their holdings has been slow to win over fans this year. That may change in 2021.

This year’s meteoric rise in biotech stocks is here to stay.

JPMorgan Chase & Co. is offering tech bulls a supercharged bet on some of the year’s top-performing exchange-traded funds. Like most Wall Street concoctions, this one comes with strings attached.

Earnings have fallen more than 50% this year because of slow loan growth, lower margins, and higher provisions.The excess capital over regulatory minimums should give investors confidence banks can weather further headwinds.Future risks include lower for longer interest rates and the potential for higher taxes in the coming quarters.

The expected 2020 EPS growth rate for the Financial sector improved from -36% to -32% by the end of July '20 but has remained stagnant since.2021's expected revenue growth was greater than the 2020 percentage decline until April 10th, and then, 2020's expected percentage decline eclipsed 2021's expected revenue growth, and the difference has grown since.Banks have an excess of capital today, pending the addition to credit losses expected in the Q3 earnings releases, but at some point, the Fed will likely allow the return of capital once again via share buybacks. The big question is, when will that happen and what will be the impact on EPS?